



Received: 15 Sep 2026
Revised: 22 Sep 2026
Accepted: 30 Sep 2026
Published: 15 Oct 2026

2026: OCTOBER - IJMSDH
Page No - 26-31
DOI - 10.55640/ijmsdh-spc-05

Article Citation: Siti Rahmawati. (2026). Therapeutic Complexity in the Aging Patient: A Comparative Review of Management Strategies and Comorbidity Burdens in Hepatocellular Carcinoma and Elderly-Onset Inflammatory Bowel Disease. International Journal of Medical Science and Dental Health, 1(01), 26-31. <https://doi.org/10.55640/ijmsdh-spc-05>

Copyright: © 2026 The Authors. Published by IJMSDH under the Creative Commons CC BY License

Therapeutic Complexity in the Aging Patient: A Comparative Review of Management Strategies and Comorbidity Burdens in Hepatocellular Carcinoma and Elderly-Onset Inflammatory Bowel Disease

Siti Rahmawati

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Abstract

Background: The management of gastrointestinal pathologies in the elderly presents a unique clinical challenge, particularly when distinguishing between chronological age and physiological frailty. This review examines two distinct but clinically overlapping conditions prevalent in aging populations: Hepatocellular Carcinoma (HCC) and Inflammatory Bowel Disease (IBD). **Methods:** We conducted a comprehensive review of recent literature focusing on therapeutic outcomes, safety profiles, and comorbidity interactions. The analysis centers on the Barcelona Clinic Liver Cancer (BCLC) strategy for HCC and the risk-benefit profile of biological therapies in elderly IBD patients. **Results:** In HCC management, evidence suggests that older age is not an independent predictor of worse survival; rather, comorbidities dictate outcomes. Advanced locoregional therapies, including Transarterial Chemoembolization (TACE) and radioembolization, show efficacy in elderly cohorts, though ischemia-induced autophagy remains a resistance mechanism. Conversely, in elderly IBD, age acts as an independent risk factor for severe infections and adverse events associated with Anti-TNF therapy. While efficacy remains comparable to younger cohorts, discontinuation rates are significantly higher due to safety concerns, including lymphoma and non-melanoma skin cancer risks. Furthermore, extra-intestinal comorbidities, specifically chronic kidney disease and metabolic disorders, significantly complicate the management of both conditions. **Conclusion:** Effective management of HCC and IBD in the elderly requires a paradigm shift from age-based exclusions to comorbidity-based stratification. Personalized therapeutic strategies that account for immunosenescence and renal function



are essential to optimize survival and minimize iatrogenic harm in this vulnerable demographic.

Keywords: Hepatocellular Carcinoma, Inflammatory Bowel Disease, Geriatric Gastroenterology, Immunosenescence, Transarterial Chemoembolization, Anti-TNF Therapy, Comorbidity Profiling.

Introduction

The global demographic landscape is undergoing a profound transformation, characterized by a rapid expansion of the geriatric population. As life expectancy increases, clinicians are increasingly confronted with the challenge of managing complex, chronic gastrointestinal and hepatic pathologies in patients with diminished physiological reserves. Among the most significant burdens in this demographic are Hepatocellular Carcinoma (HCC) and Inflammatory Bowel Disease (IBD). While distinct in their pathophysiology—one a malignancy often driven by chronic liver injury, the other a chronic immune-mediated inflammatory disorder—both conditions share a critical intersection: their management is heavily influenced by the aging process, immunosenescence, and the accumulation of comorbidities.

Historically, advanced age was often viewed as a contraindication for aggressive therapeutic interventions. In the context of HCC, elderly patients were frequently excluded from clinical trials or denied curative treatments such as resection or transplantation solely based on chronological age. Similarly, in IBD, the use of potent immunomodulators and biological therapies was often avoided in older adults due to fears of infection and malignancy, leading to undertreatment and prolonged corticosteroid dependence. However, recent advancements in clinical staging and therapeutic pharmacokinetics have prompted a re-evaluation of these conservative approaches.

The current clinical paradigm is shifting towards a more nuanced understanding of "biological age" versus "chronological age." Recent guidelines regarding the Barcelona Clinic Liver Cancer (BCLC) strategy emphasize prognosis prediction that incorporates liver function and performance status rather than age alone [18]. Concurrently, the rising incidence of elderly-onset IBD necessitates a deeper understanding of how modern therapies, such as anti-tumor necrosis factor (anti-TNF) agents, interact with an aging immune system [14, 23].

This review aims to synthesize contemporary evidence regarding the management of HCC and IBD in the aging population. We will explore the efficacy and safety of locoregional therapies for HCC, including transarterial chemoembolization (TACE) and radioembolization, and contrast

this with the therapeutic landscape of IBD, focusing on the risks associated with immunomodulation. Furthermore, we will critically analyze the impact of key comorbidities—specifically renal insufficiency, metabolic disease, and vascular pathologies—on therapeutic decision-making, arguing that comorbidity profiling is a superior predictor of outcomes compared to age alone.

Methods

This article employs a narrative review methodology to synthesize existing literature regarding the management of HCC and IBD in elderly populations. We utilized a comprehensive search strategy focusing on peer-reviewed articles, randomized controlled trials, and meta-analyses published predominantly within the last two decades, with a specific focus on updates from 2015 to 2025 to capture the most recent therapeutic guidelines.

The selection criteria prioritized studies that addressed the following domains: (1) Staging and sub-classification of HCC in intermediate and advanced stages; (2) Efficacy and safety of locoregional therapies (TACE, ablation, radioembolization); (3) Management of elderly-onset IBD and the safety profile of biological therapies; and (4) The impact of non-GI comorbidities, such as renal disease and neurological conditions, on GI treatment outcomes.

We integrated data from key clinical guidelines, including the ESMO clinical practice guidelines for HCC [17] and recent updates on BCLC strategies [18]. For IBD, we analyzed cohort studies examining the risk of lymphoproliferative disorders and infections associated with thiopurines and anti-TNF agents. The synthesis of this data allows for a comparative analysis of how aging impacts treatment strategies across two distinct gastrointestinal disciplines.

Results

Hepatocellular Carcinoma: Staging and Locoregional Interventions

The landscape of HCC management has evolved significantly, particularly for patients presenting with intermediate (Stage B) and advanced (Stage C) disease. The heterogeneity of the patient population in these stages has long been a confounding factor in determining optimal treatment. Golfieri et al. highlighted the necessity for a subclassification of BCLC stages B and C to better tailor therapies to patient prognosis [6]. This is particularly relevant for the elderly, where the "one-size-fits-all" approach of the past often led to suboptimal outcomes.

Locoregional therapies remain the cornerstone of treatment for unresectable HCC. Transarterial



chemoembolization (TACE) has demonstrated a survival benefit in randomized controlled trials compared to symptomatic treatment alone [15, 16]. However, the efficacy of TACE is not uniform. Li and Ni reported on the current status of combination therapy, noting that the synergy between TACE and local ablation can offer improved local tumor control compared to TACE alone [8]. This combination is theoretically attractive for elderly patients who may not be candidates for major hepatic resection but require more aggressive local control than embolization alone can provide.

Furthermore, trans-arterial radioembolization (TARE) has emerged as a viable alternative for intermediate-advanced HCC. A systematic review by Rognoni et al. suggests that TARE is a safe and effective option, potentially offering a better side-effect profile than conventional chemoembolization, which is a critical consideration for frail elderly patients [14].

A critical biological insight into treatment resistance in HCC involves the tumor microenvironment's response to therapy. Gade et al. demonstrated that ischemia—the very mechanism by which embolization therapies work—can induce quiescence and autophagy dependence in hepatocellular carcinoma cells [7]. This suggests that while we starve the tumor of blood supply, the metabolic stress may trigger survival mechanisms that lead to dormancy and eventual recurrence, a factor that must be considered when predicting long-term survival in older patients with limited physiological resilience.

Inflammatory Bowel Disease: The Challenge of Immunosenescence

In parallel to the complexities of HCC, the management of IBD in the elderly requires navigating a narrow therapeutic window. The elderly IBD population is composed of two distinct groups: those with long-standing disease aging into the geriatric bracket, and those with elderly-onset IBD. Sousa et al. and John et al. have reviewed the management strategies for these groups, emphasizing that while the inflammatory burden must be controlled, the collateral damage of therapy is higher in older adults [13, 14].

Biological therapies, particularly anti-TNF agents, have revolutionized IBD care. However, their safety profile in the elderly is a subject of intense scrutiny. Lobatón et al. assessed the efficacy and safety of anti-TNF therapy in this demographic, finding that while efficacy is comparable to younger cohorts, the risk of adverse events is elevated [23]. Specifically, Cottone et al. identified advanced age as an independent risk factor for severe infections and mortality in patients receiving anti-TNF therapy [22].

The risk of malignancy is another paramount concern. Siegel et al. conducted a meta-analysis highlighting the risk of lymphoma associated with combination anti-TNF and immunomodulator therapy [17]. Furthermore, Long et al. identified an increased risk of melanoma and non-melanoma skin cancer among IBD patients, a risk that is naturally compounded by the baseline increased risk of skin cancer in the aging population [18]. These findings are supported by Beaugerie et al., who noted lymphoproliferative disorders in patients receiving thiopurines [19]. Consequently, Desai et al. observed that older age is associated with a higher rate of discontinuation of anti-TNF therapy, often due to these safety concerns rather than a lack of therapeutic response [21].

The Intersection of Comorbidities

The management of both HCC and IBD cannot occur in isolation from the patient's general health status. Comorbidities play a decisive role in treatment eligibility and outcomes. Chronic kidney disease (CKD) is a prevalent comorbidity in the elderly that complicates drug dosing and contrast usage. Chang et al. highlighted that nonadherence to oral antihyperglycemic medication significantly increases the risk of end-stage renal disease, illustrating the cascade effect of metabolic mismanagement on organ function [9]. Additionally, preventative measures such as the 23-valent pneumococcal polysaccharide vaccine have been studied for their potential to reduce the risk of renal progression in older patients with CKD, suggesting that holistic care can mitigate some comorbidity burdens [10].

Neurological comorbidities also intersect with gastrointestinal health. Chi et al. established a link between Alzheimer's disease and the risk of stroke, emphasizing the vascular fragility of this patient population [11]. These systemic vascular and metabolic issues are critical when considering therapies like TACE for HCC, which carries a risk of post-embolization syndrome and vascular complications, or when managing IBD, where systemic inflammation can exacerbate cardiovascular risk.

Recent data from Kanneganti et al. provides a crucial synthesis of these factors in HCC patients, suggesting that older age itself is not associated with worse survival, but comorbidities are the primary drivers of mortality [19]. This aligns with findings in IBD by Kariyawasam et al., who noted that comorbidities rather than age are associated with the use (or non-use) of immunomodulators [16].

Discussion and Analysis

The Primacy of Comorbidity Over Chronology



The synthesis of data from both HCC and IBD literature points to a unified conclusion: chronological age is an increasingly irrelevant metric for therapeutic decision-making. The 2022 update to the BCLC strategy for HCC prognosis explicitly incorporates patient performance status, acknowledging that a fit 80-year-old may be a better candidate for locoregional therapy than a frail 60-year-old with multiple comorbidities [18]. This is supported by the findings of Kanneganti et al., which decouple age from survival outcomes when controlling for comorbid conditions [19].

In the realm of IBD, the data reflects a similar trend. Kariyawasam et al. demonstrated that the hesitation to prescribe immunomodulators is often driven by the presence of comorbidities rather than age itself [16]. However, this hesitation creates a paradox where elderly patients are under-treated for their inflammation, potentially leading to complications that are just as dangerous as the side effects of the drugs being avoided. The "start low and go slow" approach remains valid, but "do not start" based solely on a birth year is no longer evidence-based.

Mechanistic Insights and Therapeutic Resistance

A deeper analysis of the biological mechanisms at play reveals why elderly patients may respond differently to standard therapies. In HCC, the work by Gade et al. on ischemia-induced autophagy offers a profound insight into why TACE may fail to produce a complete cure [7]. Autophagy is a cellular survival mechanism where cells recycle their own components to survive stress (such as nutrient deprivation caused by embolization). In aging tissues, autophagic flux is often dysregulated. If tumor cells in elderly patients rely heavily on autophagy to survive the ischemic stress of TACE, combining embolization with autophagy inhibitors (like chloroquine or newer agents) could theoretically enhance efficacy. This is a vital area for future research, linking basic cell biology to geriatric oncology outcomes.

Similarly, in IBD, the phenomenon of immunosenescence—the gradual deterioration of the immune system—alters the risk-benefit calculation of biological therapies. The elderly immune system is less capable of mounting a robust defense against novel pathogens, which explains the findings by Cottone et al. regarding the increased risk of severe infections with anti-TNF therapy [22]. The suppression of TNF-alpha, a critical cytokine for granuloma formation and intracellular pathogen defense, when combined with a naturally weakening immune surveillance system, creates a perfect storm for opportunistic infections. This mechanistic understanding underscores the need for vigilant monitoring and perhaps distinct dosing intervals for geriatric populations.

Optimizing Locoregional Approaches in HCC

The management of HCC in the elderly requires a strategic balance between tumor control and liver function preservation. The liver's regenerative capacity diminishes with age, making extensive resections riskier. This elevates the importance of locoregional therapies discussed by Makary et al. [13]. The integration of TACE with local ablation represents a "middle ground" that offers potential curative intent without the physiological stress of surgery [8].

However, the specific technique of embolization matters. The move toward microspheres and drug-eluting beads, and potentially radioembolization [14], allows for more targeted delivery of cytotoxic payloads, minimizing systemic exposure. This is crucial for elderly patients who may have underlying renal insufficiency, as highlighted by the risks associated with contrast agents and potential nephrotoxicity. The connection between diabetes, medication adherence, and renal health [9] further complicates this picture. An elderly HCC patient with diabetic nephropathy requires a highly modified TACE protocol to avoid precipitating acute kidney injury, a complication that carries high mortality in this group.

Safety Signals in Elderly IBD Management

The safety data regarding IBD therapies in the elderly necessitates a cautious but proactive approach. The association between anti-TNF therapy and lymphoma [17] and skin cancer [18] cannot be ignored. The elderly skin is already prone to actinic damage and oncogenic mutations; adding an immunomodulator that reduces tumor surveillance increases the risk of non-melanoma skin cancers. This necessitates that gastroenterologists managing elderly IBD patients must also act as vigilant primary care physicians, ensuring regular dermatological screening.

Furthermore, the risk of lymphoproliferative disorders, particularly with thiopurines [19], suggests that these agents should perhaps be used more sparingly in the elderly, or replaced by newer biologics with more gut-specific mechanisms of action (such as anti-integrins or anti-interleukins), which may offer a safer systemic profile, although long-term data in the elderly for these newer agents is still accumulating [24]. The higher discontinuation rates observed by Desai et al. [21] reflect the real-world difficulty of maintaining these therapies; clinicians often withdraw effective drugs at the first sign of a mild adverse event due to fear of the "frail elderly" label, potentially destabilizing the disease.

The Role of Vaccination and Preventative Care

An often-overlooked aspect of managing these chronic conditions in the elderly is the role of preventative medicine. The study by Chang et al. regarding the pneumococcal vaccine and



renal progression [10] serves as a powerful reminder of systemic interconnectivity. In patients receiving immunosuppressive therapy for IBD, or those with cirrhosis and HCC who are essentially immunocompromised, vaccination status is a critical determinant of survival. Preventing secondary infections (pneumonia, influenza) preserves physiological reserve, preventing the "acute-on-chronic" deteriorations that are often fatal in this demographic.

Detailed Analysis of Renal and Vascular Comorbidities

The interplay between gastrointestinal pathology and renal/vascular health is a critical determinant of patient trajectory, yet it is often treated as a secondary concern. In the context of HCC and IBD, renal function is not merely a bystander but a central player in therapeutic viability. As highlighted by Chang et al. [9], the nonadherence to oral antihyperglycemic medication significantly increases the risk of end-stage renal disease (ESRD). This is particularly relevant for the HCC population, where Non-Alcoholic Steatohepatitis (NASH) and metabolic syndrome are increasingly becoming primary drivers of carcinogenesis. An elderly patient with NASH-induced HCC and comorbid diabetes represents a phenotype of extreme vascular and renal fragility.

When we consider the administration of contrast media for diagnostic imaging (CT/MRI) or therapeutic interventions (TACE), the baseline renal function becomes the rate-limiting step. Contrast-induced nephropathy (CIN) in an elderly patient can lead to permanent loss of renal function, necessitating dialysis, which essentially eliminates eligibility for liver transplantation and severely hampers quality of life. Therefore, the management of diabetes and hypertension—often delegated to primary care—must be aggressively monitored by the specialist treating the HCC.

Furthermore, the vascular implications extend beyond the kidney. Chi et al. described the association between Alzheimer's disease and stroke risk [11]. This neuro-vascular link is pertinent because chronic inflammation, a hallmark of both IBD and advanced liver disease, is a driver of endothelial dysfunction. Systemic inflammation increases arterial stiffness and promotes coagulopathy. In IBD patients, the chronic inflammatory state is a known risk factor for thromboembolic events (DVT/PE). In the elderly, where mobility is already reduced and vascular compliance is low, this risk is exponentially higher. The decision to use Janus Kinase (JAK) inhibitors, for example, in an elderly IBD patient must be weighed heavily against the black-box warnings regarding thrombosis and major adverse cardiovascular events (MACE).

The aggressive management of these comorbidities is not ancillary; it is central to the GI management plan. For

instance, the use of statins, often prescribed for cardiovascular risk, has been shown in some observational studies to have chemopreventive effects in HCC and potential anti-inflammatory effects in IBD, though more robust data is needed. Conversely, the use of diuretics for ascites in HCC can precipitate renal failure if not balanced against intravascular volume status. The intricate dance of polypharmacy in the elderly—managing the liver, the gut, the kidneys, and the heart simultaneously—requires a level of vigilance that transcends standard guidelines.

Conclusion

The management of Hepatocellular Carcinoma and Inflammatory Bowel Disease in the aging population represents a frontier of modern medicine where oncology, immunology, and geriatrics must converge. The evidence synthesized in this review demonstrates that while chronological age serves as a demographic marker, it is a poor guide for clinical decision-making. Instead, the focus must shift to biological age, defined by comorbidity burden, renal function, and immune resilience.

In HCC, the evolution of BCLC staging and the refinement of locoregional therapies like TACE and radioembolization offer hope for extended survival even in advanced age, provided that ischemia-induced resistance mechanisms and renal risks are managed. In IBD, the goal remains the induction of remission, but the path requires careful navigation of immunosenescence, prioritizing safety signals like infection and malignancy over aggressive immunosuppression.

Ultimately, the successful treatment of the elderly GI patient lies in personalization. It requires a move away from exclusionary protocols based on birth year and toward inclusionary protocols based on physiological fitness. Future research must focus on elucidating the molecular mechanisms of aging within the liver and the gut, such as autophagy and immunosenescence, to develop targeted therapies that are both effective and safe for this rapidly growing patient population.

References

1. Golfieri R, Bargellini I, Spreafico C, et al. Patients with Barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a subclassification. *Liver Cancer*. 2019; 8: 78-91.
2. Gade TPF, Tucker E, Nakazawa MS, et al. Ischemia induces quiescence and autophagy dependence in hepatocellular carcinoma. *Radiology*. 2017; 283: 702-710.
3. Li W, Ni C-F. Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma. *Abdom Radiol*. 2019; 44: 2268-2275.



4. Chang PY, Chien LN, Lin YF, et al. Nonadherence of oral antihyperglycemic medication will increase risk of end-stage renal disease. *Medicine*. 2015; 94: e2051.
5. Chang PY, Lin CJ, Chen HC, et al. 23-valent pneumococcal polysaccharide vaccine and the risk of renal progression in older patients with chronic kidney disease. *Prev Med*. 2023; 177: 107753.
6. Chi NF, Chien LN, Ku HL, et al. Alzheimer disease and risk of stroke: a population-based cohort study. *Neurology*. 2013; 80: 705–711.
7. Lin LY, Warren-Gash C, Smeeth L, et al. Data resource profile: the national health insurance research database (NHIRD). *Epidemiol Health*. 2018; 40: e2018062.
8. Makary MS, Khandpur U, Cloyd JM, et al. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. *Cancers*. 2020; 12: 1914.
9. Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. *Oncotarget*. 2016; 7: 72343–72355.
10. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet*. 2002; 359: 1734–1739.
11. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology*. 2002; 35: 1164–1171.
12. Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2025; 36: 491–506.
13. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol*. 2022; 76: 681–693.
14. Kanneganti M, Al-Hasan M, Bourque S, et al. Older age but not comorbidity is associated with worse survival in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2024; 24: 1038–1041.
15. White DL, Thrift AP, Kanwal F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. *Gastroenterology*. 2000; 152: 812–820.
16. Hruz P, Juillerat P, Kullak-Ublick G-A, Schoepfer AM, Mantzaris GJ, Rogler G. Management of the elderly inflammatory bowel disease patient. *Digestion*. 2020;101(Suppl. 1):105-19.
17. John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of inflammatory bowel disease in the elderly. Current treatment options in gastroenterology. 2016;14:285-304.
18. Sousa P, Bertani L, Rodrigues C. Management of inflammatory bowel disease in the elderly: A review. *Digestive and liver disease*. 2023;55(8):1001-9.
19. Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. *Therapeutic Advances in Gastroenterology*. 2021;14:17562848211023399.
20. Kariyawasam VC, Kim S, Mourad FH, Selinger CP, Katelaris PH, Brian Jones D, et al. Comorbidities rather than age are associated with the use of immunomodulators in elderly-onset inflammatory bowel disease. *Inflammatory Bowel Diseases*. 2019;25(8):1390-8.
21. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clinical Gastroenterology and Hepatology*. 2009;7(8):874-81.
22. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology*. 2012;143(2):390-9. e1.
23. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *The Lancet*. 2009;374(9701):1617-25.
24. Fidler H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segal S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. *Gut*. 2009;58(4):501-8.
25. Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. *Inflammatory bowel diseases*. 2013;19(2):309-15.
26. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clinical Gastroenterology and Hepatology*. 2011;9(1):30-5.
27. Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Alimentary pharmacology & therapeutics*. 2015;42(4):441-51.
28. M. Noor N, Bourke A, Subramanian S. Novel therapies in inflammatory bowel disease—An update for clinicians. *Alimentary Pharmacology & Therapeutics*. 2024;60(9):1244-60.